Bill Text: IL HR0138 | 2021-2022 | 102nd General Assembly | Introduced
Bill Title: Declares March 2021 as "Precision Medicine and Biomarker Testing Awareness Month" in the State of Illinois.
Spectrum: Bipartisan Bill
Status: (Passed) 2021-05-06 - Resolution Adopted [HR0138 Detail]
Download: Illinois-2021-HR0138-Introduced.html
| |||||||
| |||||||
| |||||||
1 | HOUSE RESOLUTION
| ||||||
2 | WHEREAS, Precision medicine, which is also called | ||||||
3 | personalized health care or individualized medicine, is an | ||||||
4 | evolving field in which healthcare providers use analysis of a | ||||||
5 | patient's biospecimen, known as biomarker testing, to | ||||||
6 | determine which medical treatments will work best for each | ||||||
7 | patient; and
| ||||||
8 | WHEREAS, By combining the data from biomarker testing with | ||||||
9 | an individual's medical history, circumstances, and values, | ||||||
10 | healthcare providers can direct a patient to targeted | ||||||
11 | treatment, which benefits both patients and the overall | ||||||
12 | healthcare system; and
| ||||||
13 | WHEREAS, The field of precision medicine holds great | ||||||
14 | promise in ensuring the delivery of the right treatment to the | ||||||
15 | right patient at the right time; and
| ||||||
16 | WHEREAS, Sixty percent of treatments in preclinical | ||||||
17 | development rely on biomarker data; and
| ||||||
18 | WHEREAS, Biomedicine and the understanding of the | ||||||
19 | characteristics of a patient's disease that informs precision | ||||||
20 | medicine is evolving rapidly; and
|
| |||||||
| |||||||
1 | WHEREAS, Healthcare providers are increasingly gaining | ||||||
2 | access to new technologies, such as biomarker testing, that | ||||||
3 | can help identify gene mutations, alterations, or protein | ||||||
4 | expressions specific to individual patients; and
| ||||||
5 | WHEREAS, Health outcomes are improved through the use of | ||||||
6 | precision medicine; for example, patients with certain types | ||||||
7 | of lung cancer who received biomarker testing had a 28 percent | ||||||
8 | reduction in mortality; and
| ||||||
9 | WHEREAS, The National Academy of Medicine considers | ||||||
10 | biomarker tests to be "key to unlocking the promise" of | ||||||
11 | personalized health care; and
| ||||||
12 | WHEREAS, Biomarker testing is available for an | ||||||
13 | ever-increasing range of conditions and diseases, but patient | ||||||
14 | access to these tests is not keeping pace with the rate of | ||||||
15 | innovation; and
| ||||||
16 | WHEREAS, A lack of awareness among providers and patients, | ||||||
17 | a lack of common terminology, and deficient coverage policies | ||||||
18 | by both public and private payers are preventing effective | ||||||
19 | adoption and integration of biomarker testing into precision | ||||||
20 | medicine and appropriate awareness and education about the | ||||||
21 | ways biomarker testing can be used to support diagnosis, | ||||||
22 | treatment, and monitoring of patients in a personalized way; |
| |||||||
| |||||||
1 | and
| ||||||
2 | WHEREAS, The Illinois Department of Public Health and | ||||||
3 | other relevant partners seek to promote awareness, education, | ||||||
4 | and action related to improving access to biomarker testing; | ||||||
5 | therefore, be it
| ||||||
6 | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | ||||||
7 | HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | ||||||
8 | we declare March 2021 as "Precision Medicine and Biomarker | ||||||
9 | Testing Awareness Month" to raise awareness, encourage | ||||||
10 | education, and improve understanding of the ways biomarker | ||||||
11 | testing can be used to support diagnosis, treatment, and | ||||||
12 | monitoring of patients in a personalized way and the | ||||||
13 | importance of ensuring access to these promising technologies.
|